Christopher Aker - 10 Aug 2023 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Sr. VP & General Counsel
Signature
Christopher Aker
Issuer symbol
RGLS
Transactions as of
10 Aug 2023
Net transactions value
$0
Form type
4
Filing time
14 Aug 2023, 17:12:09 UTC
Previous filing
17 Jan 2023
Next filing
17 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +393,750 $0.000000 393,750 10 Aug 2023 Common Stock 393,750 $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.